Thus, these findings provide oncogenic and mechanistic evidence regarding the involvement of FOXM1 in glycolysis and cancer progression and suggest a novel therapeutic target for NPC (Figure 6E). The gene discussed is FOXM1; the disease is nasopharyngeal carcinoma.